<![CDATA[Tabelecleucel BLA Resubmitted to FDA for EBV-Positive PTLD]]>

BLA FilingtabelecleucelPositive

AI Analysis

Summary

Tabelecleucel's biologics license application has been resubmitted to the FDA for EBV-positive PTLD following feedback from a Type A meeting held in April 2026.

Outcome Details

Resubmitted following Type A meeting feedback from April 2026

Importance:6/10

Sentiment:

0.30

BLA resubmissionEBV-positive PTLDFDA regulatorycell therapy

Read the original article

Published by Cancer Network on October 1, 2026 3:02 PM

Read Original